[Splicing factor mutations in myelodysplastic syndromes].

Area of Science:

• Hematology
• Molecular Biology
• Genetics

Background:

• Splicing factor mutations are increasingly recognized as key drivers in myelodysplastic syndromes (MDS).
• Four genes (SF3B1, SRSF2, U2AF1, ZRSR2) are frequently mutated in MDS.
• Specific mutations correlate with distinct MDS subtypes, such as SF3B1 with ring sideroblasts and SRSF2 with chronic myelomonocytic leukemia.

Purpose of the Study:

• To elucidate the precise mechanisms and identify target genes affected by splicing factor mutations in MDS.
• To understand how these mutations contribute to the pathogenesis of different MDS subtypes.

Main Methods:

• RNA sequencing was employed to analyze splicing alterations induced by mutations.
• Protein structure modeling, cell line experiments, and mouse models were utilized for validation.
• Analysis focused on splice site recognition, alternative exon usage, and intron retention.

Main Results:

• SF3B1 mutations led to 3' splice site misrecognition, affecting genes like ABCB7 and PPOX involved in iron metabolism and erythropoiesis.
• SRSF2 and U2AF1 mutations primarily caused alternative exon usage in numerous genes, including known myeloid malignancy drivers.
• ZRSR2 mutations were linked to U12-type intron retention, consistent with its role in the U12 spliceosome.

Conclusions:

• Splicing factor mutations drive MDS pathogenesis through distinct mechanisms affecting RNA splicing.
• These mutations alter the expression of critical genes, contributing to the specific clinical and molecular features of MDS subtypes.
• Further research is needed to fully understand the biological consequences of these splicing alterations in MDS.